Trials / Recruiting
RecruitingNCT07078591
Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML
Phase 2 Study of Venetoclax-containing Therapy in Combination With HLA-mismatched Mobilized Peripheral Blood Mononuclear Cell Infusion for Newly Diagnosed Acute Myeloid Leukemia
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Beijing 302 Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate whether HLA-mismatched donor G-CSF mobilized peripheral blood mononuclear cell (GPBMC) infusion with venetoclax-containing regimens (microtransplant, MST) could improve survival in adult patients with newly diagnosed acute myeloid leukemia (AML).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Venetoclax | Given PO |
| DRUG | Azacitidine (AZA) | Given SC |
| DRUG | Daunorubicin | Given IV |
| DRUG | Idarubicin（IDA） | Given IV |
| DRUG | Cytarabine (Ara-C) | Given IV |
| BIOLOGICAL | GPBMC infusion | HLA-mismatched donor GPBMC infusion |
Timeline
- Start date
- 2025-06-20
- Primary completion
- 2030-06-01
- Completion
- 2031-06-01
- First posted
- 2025-07-22
- Last updated
- 2025-07-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07078591. Inclusion in this directory is not an endorsement.